This copy is for your personal, non-commercial use only. To order presentation-ready copies for distribution to your colleagues, clients or customers visit http://www.djreprints.com.

https://www.barrons.com/articles/medicine-healthcare-stocks-51663967036

Thanks to vaccines, treatments, and preventive measures, the Covid crisis has eased, even if the pernicious virus persists. The pandemic’s evolution gives healthcare companies a chance to focus on other issues, including drug-patent expirations, pricing pressures, regulatory changes, and deal making. For investors, a bear market in stocks adds another wrinkle—and an opportunity to snap up shares of the industry’s most promising companies on the cheap.

This year, Barron’s annual healthcare roundtable focuses on emerging themes across the industry, from the ability to “interrogate” biology with computational tools to the evolution of value-based care. The challenges are many, but the news is good, not only for innovative biotech and cash-rich pharmaceutical companies, but also for nimble managed-care providers and purveyors of much-needed medical devices and life-sciences tools.

Thanks to vaccines, treatments, and preventive measures, the Covid crisis has eased, even if the pernicious virus persists.

An error has occurred, please try again later.

This article has been sent to

Copyright ©2022 Dow Jones & Company, Inc. All Rights Reserved

This copy is for your personal, non-commercial use only. Distribution and use of this material are governed by our Subscriber Agreement and by copyright law. For non-personal use or to order multiple copies, please contact Dow Jones Reprints at 1-800-843-0008 or visit www.djreprints.com.